What is HRT (Hormone Replacement Therapy)? | PeptideWorld

What is HRT (Hormone Replacement Therapy)?

🧬 Hormone Health ⏱ 14 min read 🎓 Beginner – Intermediate
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. HRT is a prescription treatment that requires individual risk-benefit assessment with a licensed physician. Nothing here should substitute for a conversation with your doctor.

Hormone replacement therapy has one of the most complicated evidence histories in medicine — and one of the most consequential. A single study published in 2002 changed the prescribing practices of an entire generation of clinicians, caused millions of women to stop or never start treatment, and left a legacy of fear and under-treatment that experts are still working to correct.

That study was the Women's Health Initiative. What it found, what it got wrong, and what two decades of subsequent research have clarified is the story that underpins everything in the current HRT conversation. Understanding it is essential for any woman trying to make an informed decision.

Key Takeaways

  • The 2002 WHI trial that caused mass abandonment of HRT studied women with a mean age of 63 — ten years post-menopause, with significant cardiovascular risk. Its findings do not apply to women starting HRT close to menopause.
  • The critical "timing hypothesis": HRT started within 10 years of menopause or before age 60 has a fundamentally different benefit-risk profile from HRT started later. The cardiovascular risks identified in WHI applied mainly to older starters.
  • WHI's 20-year follow-up (2024) found no increase in breast cancer or cardiovascular deaths — and a reduction in all-cause mortality when HRT was started in women under 60 or within 10 years of their last period.
  • In November 2025, the FDA removed boxed warnings about cardiovascular disease, breast cancer, and dementia from estrogen product labelling — acknowledging that the evidence no longer supported those warnings.
  • Transdermal estrogen (patch or gel) does not carry the VTE (blood clot) or cardiovascular risk of oral estrogen — because it bypasses the liver and does not trigger clotting factor production. This distinction is clinically important.
  • The type of progestogen matters: synthetic progestins (like MPA used in WHI) carry a higher associated breast cancer risk than natural micronised progesterone. This distinction is driving a shift in clinical practice.

The WHI — What Happened and Why It Matters

The WHI Story — A Timeline

1993
The Women's Health Initiative launches — 68,000+ postmenopausal women enrolled to study long-term hormone therapy effects on cardiovascular disease, cancer, and osteoporosis.
July 2002
The combined estrogen + medroxyprogesterone acetate (MPA) arm is halted early. The monitoring board judges that risks — invasive breast cancer, cardiovascular events, stroke — outweigh benefits in the enrolled cohort. HRT prescribing collapses globally within weeks.
2004–2010
Researchers begin stratifying WHI data by age. The cardiovascular risks were concentrated in women who started HRT more than 10 years post-menopause, with average age 63. Women who started earlier showed neutral to beneficial cardiovascular effects.
2009–2017
The "timing hypothesis" emerges and is validated in multiple studies including DOPS, KEEPS, and ELITE. Women near menopause onset get different outcomes from those starting years later. Society guidance begins emphasising individualised care.
May 2024
WHI 20-year follow-up published: no increase in deaths from breast cancer or cardiovascular disease across the full trial cohort. All-cause mortality was reduced for women who started HRT under 60 or within 10 years of their last period.
Nov 2025
FDA announces removal of boxed warnings about cardiovascular disease, breast cancer, and probable dementia from estrogen product labelling. The boxed warning for endometrial cancer in estrogen-alone products is retained. ACOG commends the decision.[1]
⚠️ The Critical Methodological Flaw That Changed Everything The WHI enrolled women aged 50–79 with a mean age of 63 — women who were, on average, more than 10 years past menopause and whose cardiovascular risk was already elevated before the trial began. The risks identified (heart attack, stroke) applied primarily to this older, higher-risk population — not to women starting HRT close to menopause. When WHI data was re-analysed for women aged 50–59, the benefit-risk picture was materially different: lower total cancer incidence, and no increase in cardiovascular events. The trial was not designed to assess HRT for symptomatic perimenopausal women — yet its findings were applied universally to that population for over a decade.

The Timing Hypothesis — The Most Important Concept in HRT

The "Window of Opportunity" — What It Means in Practice

The timing hypothesis holds that there is a critical window — typically the 10 years following the onset of menopause, or age 60, whichever comes first — during which estrogen has cardiovascular-protective or neutral effects on the vascular system. Outside that window, when arterial disease has already established, estrogen may destabilise existing plaques rather than prevent their formation.

The practical implications: a woman of 52 who starts HRT shortly after menopause is in a very different risk category from a woman of 67 starting HRT for the first time. Multiple subsequent trials have confirmed that women who start within the window experience neutral to beneficial cardiovascular effects, better bone outcomes, and quality-of-life improvements that outweigh risk. The WHI's risks were real — but they were the risks of starting late, not of HRT itself.

Current clinical guidance (NAMS, ACOG, BMS, Endocrine Society) recommends HRT as appropriate for women with bothersome menopausal symptoms who are under 60 or within 10 years of menopause, individualised according to their symptom burden, medical history, and risk factors.

What HRT Actually Involves: The Hormones

HRT is not a single treatment — it is a category of treatments involving different hormones, doses, formulations, and delivery routes. Understanding the components helps make sense of why the evidence varies so much depending on what type of HRT is being studied.

Estrogen
Estrogen is the primary active component — responsible for relieving vasomotor symptoms, protecting bone, supporting vaginal and urinary health, and providing mood and cognitive benefits. Estradiol (E2) is the bioidentical form, most closely matching the estrogen naturally produced by the ovaries. Conjugated equine estrogens (CEE, brand name Premarin) — the form used in the WHI — are derived from horse urine and are considered less physiological. Women with a uterus must take estrogen with a progestogen to protect the endometrium. Women without a uterus (post-hysterectomy) can take estrogen alone.
Progestogen
Progestogen is added to protect the uterine lining from the proliferative effects of estrogen — without it, unopposed estrogen significantly increases endometrial cancer risk. Two types are used: synthetic progestins (medroxyprogesterone acetate/MPA, norethisterone, levonorgestrel) and micronised progesterone (Utrogestan, Prometrium — identical to the body's own progesterone). Evidence increasingly suggests that micronised progesterone carries a lower associated breast cancer risk than synthetic progestins — this distinction is now a significant factor in clinical prescribing decisions. The type of progestogen used in the WHI (MPA) was synthetic — its specific risk profile may not generalise to micronised progesterone.

Delivery Routes — Why "How You Take It" Matters

⚠️ Oral (Tablet / Capsule)

Oral estrogen undergoes first-pass liver metabolism — it passes through the liver before entering the bloodstream. This process triggers the liver to produce clotting factors, slightly increasing VTE (blood clot) risk, and it may also increase blood pressure and triglycerides. The WHI used oral conjugated estrogens. Oral HRT is effective and widely used, but the liver-metabolism effect is relevant for women with cardiovascular risk factors or personal/family history of VTE.

✓ Transdermal (Patch / Gel / Spray)

Transdermal estrogen bypasses liver metabolism — it absorbs directly into the bloodstream through the skin. This eliminates the clotting factor increase seen with oral estrogen, bringing VTE risk back to baseline. Multiple studies confirm that transdermal estradiol does not increase VTE risk. Transdermal delivery also avoids blood pressure and triglyceride effects. Current clinical guidance increasingly favours transdermal routes, particularly for women with any cardiovascular risk factors — and it is the route recommended for women over 60 who are starting HRT.

For local vaginal estrogen — used specifically for genitourinary syndrome of menopause (vaginal dryness, urinary symptoms) — systemic absorption is minimal regardless of route. Low-dose vaginal estrogen cream, rings, or tablets do not require a progestogen even in women with a uterus, and carry essentially no systemic risk profile.[2]

What HRT Evidence Shows for Benefits

First-Line Treatment Vasomotor Symptoms (Hot Flashes / Night Sweats) HRT is the most effective treatment for hot flashes and night sweats — the hallmark vasomotor symptoms of menopause. Studies consistently show 80–90% reduction in frequency and severity. No non-hormonal treatment approaches this efficacy. For women with severe vasomotor symptoms, HRT offers a quality-of-life improvement that few other interventions can match.
First-Line Treatment Genitourinary Syndrome of Menopause Vaginal dryness, pain during sex, urinary frequency, and recurrent UTIs — collectively the genitourinary syndrome of menopause — respond to local estrogen therapy. This is the clearest indication for HRT with the lowest risk profile. Low-dose vaginal estrogen is first-line treatment and can be used long-term without systemic concerns.
Strong Evidence Bone Density / Osteoporosis Prevention Estrogen deficiency accelerates bone loss at menopause — up to 20% of bone density can be lost in the first 5 years post-menopause without intervention. HRT prevents this accelerated loss and reduces fracture risk in appropriate candidates. This benefit is an established indication, particularly for women with early menopause or high osteoporosis risk.
Strong Evidence Sleep Quality A 2024 Korean study showed significant improvement in sleep quality scores after 1 and 3 months of HRT. Improved sleep frequently accompanies reductions in vasomotor symptoms — particularly the night sweats that fragment sleep — but estrogen also directly influences sleep architecture independent of symptom relief.
Moderate Evidence Mood & Depression Transdermal estradiol shows the most consistent antidepressant effects, particularly in perimenopausal women. The effect is more pronounced in perimenopause than late postmenopause, likely due to estrogen's modulation of serotonin and dopamine pathways. Estrogen is not a substitute for antidepressants in clinical depression, but for mood changes that are clearly hormone-driven, the response to HRT can be significant.
Moderate — Evolving Cognitive Function Estrogen plays a role in brain health — promoting synaptic growth, reducing neuroinflammation, and maintaining brain metabolism. A 2024 study linked menopause-associated estrogen decline to increased Alzheimer's risk. Early HRT initiation may preserve cognitive function; the evidence is more favourable for women who start treatment early in the menopausal transition than for those who start late.

The Progestogen Question — Type Matters

Synthetic Progestins vs Micronised Progesterone: A Clinically Important Distinction

All of the breast cancer signal associated with combined HRT in the original WHI trial was generated using medroxyprogesterone acetate (MPA) — a synthetic progestin. This is not the same compound as natural micronised progesterone (bioidentical progesterone), and the evidence increasingly suggests their risk profiles differ significantly.

The E3N cohort study (France, 80,000+ women) and subsequent analyses found that combined HRT using estrogen plus micronised progesterone was not associated with an increased breast cancer risk over 5 years — whereas combined HRT using synthetic progestins was. The UK Biobank and Nordic studies have produced broadly consistent findings. Current UK guidance (NICE, BMS) has moved toward recommending micronised progesterone over synthetic progestins where possible, and this approach is gaining traction in other jurisdictions.

Practical implication: When discussing combined HRT with your physician, asking specifically about micronised progesterone (brand names: Utrogestan, Prometrium) as opposed to synthetic progestins is clinically reasonable based on current evidence.

The Remaining Risks — An Honest Assessment

Risk Current Evidence Key Modifying Factors
Breast Cancer Combined estrogen + synthetic progestin: small but real increased risk with prolonged use (>5 years). Estrogen alone: no increase — WHI estrogen-only arm had lower breast cancer rates than placebo. Micronised progesterone: likely lower risk than synthetic progestins; more evidence needed. Type of progestogen (synthetic vs micronised), duration of use, baseline risk. Absolute risk increase is small — about 1 additional case per 1,000 women per year of use with combined synthetic therapy.
VTE (Blood Clots) Oral estrogen: modest increase in VTE risk. Transdermal estrogen: no increased VTE risk — bypasses liver and does not trigger clotting factor production. This is one of the strongest arguments for transdermal over oral routes. Route of administration is the primary modifier. Women with personal or family history of VTE should use transdermal estrogen and avoid oral estrogen.
Stroke Oral estrogen: small increase in stroke risk in some studies. Transdermal estrogen: does not appear to increase stroke risk at standard doses. Risk is primarily a route-related concern. Route of administration; baseline cardiovascular risk. Transdermal estrogen is preferred in women with cardiovascular risk factors.
Cardiovascular Disease For women under 60 or within 10 years of menopause: neutral to beneficial. For women who start after 60 or >10 years post-menopause with established cardiovascular disease: not recommended as a first-line approach. WHI 20-year follow-up showed no increase in cardiovascular deaths overall. Timing of initiation is the primary modifier. Age at start and years since menopause determine the benefit-risk balance more than any other factor.
Ovarian Cancer Small increased risk with prolonged use (>10 years) in some observational studies. Risk appears to have attenuated in more recent data. Signal is modest and contested; recent meta-analyses show reduced risk signal in more recent cohorts. Duration of use; type of HRT. Clinically significant mainly for women planning very long-term (10+ year) HRT with high ovarian cancer risk.
Endometrial Cancer Estrogen alone in women with a uterus: significantly increases endometrial cancer risk — this risk is real and requires progestogen to counteract. Adequately progestogen-balanced combined HRT: does not increase endometrial cancer risk. The boxed warning for this indication was retained in the 2025 FDA label update. The presence of a uterus; adequacy of progestogen protection. Women post-hysterectomy can safely take estrogen alone.

Who Should Not Use Systemic HRT

Contraindications — When Systemic HRT Is Not Appropriate

  • Active or recent breast cancer (or any hormone receptor-positive cancer)
  • Personal history of VTE (deep vein thrombosis or pulmonary embolism) — unless using transdermal estrogen with specialist input
  • Active cardiovascular disease or stroke if starting HRT after age 60 or >10 years post-menopause
  • Undiagnosed or unexplained vaginal bleeding (must be investigated first)
  • Active liver disease or significantly impaired liver function
  • Known thrombogenic mutations (e.g. Factor V Leiden) — specialist assessment required

Note: Local (vaginal) estrogen for genitourinary symptoms has a significantly different risk profile from systemic HRT and is appropriate in many women where systemic treatment is contraindicated. This should be discussed explicitly with a clinician.

📋 November 2025: FDA Removes Key Boxed Warnings from Estrogen Products In November 2025, the FDA — following an expert panel review in July 2025 — announced that boxed warnings about cardiovascular disease, breast cancer, and probable dementia would be removed or revised from systemic estrogen product labelling. The FDA acknowledged that the evidence no longer supported these warnings as blanket cautions applicable to all women. The American College of Obstetricians and Gynecologists commended the change, noting it would improve access for perimenopausal women who need treatment. The endometrial cancer warning for estrogen-alone products was maintained.

Considering HRT and want to understand your options?

Our free quiz helps you think through your situation before speaking with a clinician.

Take Our Peptide Plan Quiz →

References

  1. Patient Care Online. Hormone Replacement Therapy After the WHI: Clinician's Evidence Timeline (2002–2025). March 2026. Available from: https://www.patientcareonline.com
  2. PMC. Menopausal Hormone Therapy — Risks, Benefits and Emerging Options: A Narrative Review. Nov 2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12652300/
  3. NIH/NHLBI. Researchers review findings and clinical messages from the Women's Health Initiative 30 years after launch. 2024. Available from: https://www.nih.gov
  4. Yale School of Medicine. After Decades of Misunderstanding, Menopause is Finally Having Its Moment. 2025. Available from: https://medicine.yale.edu
  5. Frontiers in Endocrinology. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. 2021. Available from: https://www.frontiersin.org
  6. Stanford Lifestyle Medicine. Menopause Hormone Therapy Is Making a Comeback: Is it Safe and Right for You? Available from: https://lifestylemedicine.stanford.edu
  7. PMC. Reconsidering Hormone Replacement Therapy: Current Insights on Utilisation in Premenopausal and Menopausal Women. Oct 2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12565178/